Skip to main content
P

Prestige Biologics Co., Ltd. — Investor Relations & Filings

Ticker · 334970 ISIN · KR7334970001 KO Manufacturing
Open in API
Filings indexed 201 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country KR South Korea
Listing KO 334970

About Prestige Biologics Co., Ltd.

https://prestigebiologics.com/en/

Prestige Biologics is a biopharmaceutical Contract Development and Engineering Manufacturing Organization (CDEMO) that provides end-to-end solutions for the entire lifecycle of a drug, from initial development to commercial production. The company specializes in antibody-based therapeutics and offers a comprehensive suite of services including process development, analytical testing, manufacturing of drug substances and drug products, and secondary packaging for clinical trials. It supports clients through all clinical stages by providing services optimized for their specific needs, utilizing advanced equipment and GMP-compliant facilities.

Recent filings

Filing Released Lang Actions
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings
2026-04-30 Korean
단일판매ㆍ공급계약해지
Regulatory Filings
2026-04-30 Korean
단기차입금증가결정
Capital/Financing Update Classification · 1% confidence The document is a formal announcement detailing the decision to increase short-term borrowings (단기차입금 증가결정), including amounts, purpose, and board resolution details. This clearly describes a financing activity (debt financing update). Therefore, it fits the “Capital/Financing Update” category.
2026-04-23 Korean
자산재평가결과(자율공시)
Regulatory Filings Classification · 1% confidence The document is a voluntary regulatory disclosure (자율공시) detailing the results of an asset revaluation (토지 재평가결과) including revaluation amounts, accounting entries, and related notes. It is not an annual or interim report, earnings release, proxy statement, dividend notice, or share issuance document. It is a standalone regulatory announcement of a specific accounting event with no dedicated category, so it falls under the general “Regulatory Filings” fallback.
2026-04-02 Korean
자산재평가실시결정(자율공시)
Regulatory Filings Classification · 1% confidence The document is a standalone voluntary disclosure (“자율공시”) announcing an asset revaluation decision under K-IFRS (land revaluation, book values, valuation agency, purpose, dates). It is not an annual or interim report, earnings release, capital raising notice, share issuance, director dealing, M&A, dividend, or any other specific category. It does not itself publish a detailed report but announces the decision. Therefore it falls into the fallback category of general regulatory filings.
2026-03-26 Korean
전환가액의조정
Capital/Financing Update Classification · 1% confidence The document is a formal regulatory filing from Prestige Biologics regarding the adjustment of the conversion price for convertible bonds (CB). It details the change in conversion price, the number of convertible shares, and the underlying reasons (market price decline). This type of disclosure relates to capital structure changes and financing instruments, which falls under the 'Capital/Financing Update' category.
2026-03-20 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.